E
Aditxt, Inc. ADTX
$2.30 -$0.01-0.43% NASDAQ
Recommendation
Prev Close
$2.31
Volume
137,331
Avg Vol (90D)
2,138,878
Market Cap
$2.68M
Dividend & Yield
--
52-Week Range
$2.04 - $27,200.00
P/E (TTM)
--
EPS (TTM)
-$100.70
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
Aditxt's Subsidiary Pearsanta Gets IRB Approval
4/22/2025 - TipRanks Financial Blog
Dr. Charles Howe of the Mayo Clinic's Neuroimmunology Department to Join Aditxt Weekly Update ...
4/17/2025 - GuruFocus
Dr. Charles Howe of the Mayo Clinics Neuroimmunology Department to Join Aditxt Weekly Update on May 2, 2025, to Discuss Newly Announced Preclinical Study Results Sponsored by Aditxts Subsidiary Adimune
4/17/2025 - Business Wire
Aditxt Subsidiary Pearsanta Receives IRB Approval to Initiate Clinical Study of Blood-Based ...
4/16/2025 - GuruFocus
Aditxt Subsidiary Pearsanta Receives IRB Approval to Initiate Clinical Study of Blood-Based ...
4/16/2025 - GuruFocus
Aditxt Subsidiary Pearsanta Receives IRB Approval to Initiate Clinical Study of Blood-Based Diagnostic for Endometriosis with Patient Enrollment Planned to Begin in May 2025
4/16/2025 - Business Wire
Aditxt (ADTX) Study Reinforces ADI-100's Promise in Autoimmune Treatments ADTX Stock News
4/14/2025 - GuruFocus
Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to ...
4/14/2025 - GuruFocus
Aditxt announces results from ADI-100 study
4/14/2025 - TipRanks Financial Blog
Aditxt announces results from ADI-100 study
4/14/2025 - The Fly
Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials
4/14/2025 - Business Wire
Aditxt Weekly Update to Highlight Recent Events, Including Regaining Compliance with Nasdaq ...
4/11/2025 - GuruFocus
Aditxt Weekly Update to Highlight Recent Events, Including Regaining Compliance with Nasdaq ...
4/11/2025 - GuruFocus
Aditxt Weekly Update to Highlight Recent Events, Including Regaining Compliance with Nasdaq Listing Requirements
4/11/2025 - Business Wire
Why Aditxt Inc. (ADTX) Went Down On Thursday?
4/10/2025 - Insider Monkey
Why Aditxt Inc. (ADTX) Went Down On Thursday?
4/10/2025 - Yahoo! Finance: News
Aditxt, Inc. (NASDAQ: ADTX) Regains Compliance with Nasdaq Listing Requirements ADTX Stock News
4/9/2025 - GuruFocus
Aditxt, Inc. (NASDAQ: ADTX) Regains Compliance with Nasdaq Listing Requirements
4/9/2025 - GuruFocus
Aditxt, Inc. (NASDAQ: ADTX) Regains Compliance with Nasdaq Listing Requirements
4/9/2025 - Business Wire
Appili President and CEO, Don Cilla Will Join Aditxt Co-founder and CEO, Amro Albanna, at the ...
4/2/2025 - GuruFocus
Appili President and CEO, Don Cilla to Join Aditxt CEO, Amro Albanna for Aditxt Weekly Update ...
4/2/2025 - GuruFocus
Appili Therapeutics CEO to join Aditxt CEO for weekly update on April 4
4/2/2025 - The Fly
Appili President and CEO, Don Cilla to Join Aditxt CEO, Amro Albanna for Aditxt Weekly Update on April 4, 2025
4/2/2025 - Globe Newswire
Appili President and CEO, Don Cilla Will Join Aditxt Co-founder and CEO, Amro Albanna, at the Aditxt Weekly Update on April 4, 2025
4/2/2025 - Business Wire
Upcoming Aditxt Weekly Update to Highlight Pearsanta's Acquisition of the Adductomics-Based ...
3/28/2025 - GuruFocus
Income Statement
Total Revenue (TTM)
$134.10K
EBITDA (TTM)
-$27.25M
EBIT (TTM)
-$27.86M
Net Income (TTM)
-$34.45M
Balance Sheet
Total Assets (Q)
$32.14M
Total Debt (Q)
$6.92M
Total Liabilities (Q)
$23.86M
Book Value Per Share (Q)
$3.83
Cash Flow
Cash from Operations (TTM)
-$16.76M
Cash from Investing (TTM)
-$5.00M
Cash from Financing (TTM)
$22.50M
Net Change in Cash (TTM)
$736.00K
Filings
Filing Date
Monday, March 31, 2025
Period Date
Tuesday, December 31, 2024
Next Filing
Week of May 19 and 23 (est)
Price History
Loading...
Beta
2.96
7-Day Total Return
-8.00%
30-Day Total Return
-83.80%
60-Day Total Return
-92.03%
90-Day Total Return
-97.42%
Year to Date Total Return
-95.28%
1-Year Total Return
-99.99%
2-Year Total Return
-100.00%
3-Year Total Return
-100.00%
5-Year Total Return
--
52-week Low
Apr 17, 2025 - $2.04
52-week High
Jul 17, 2024 - $27,200.00
Valuation
Market Cap
$2.68M - Nano Cap
Enterprise Value
$16.55M
Price/Sales (TTM)
0.89
Price/Book (Q)
0.60
Dividends and Shares
Shares Outstanding
51.90K
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.aditxt.com
Phone Number
650 870 1200
Address
737 North Fifth Street
Richmond, VA 23219
Country
United States
Year Founded
2017
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Aditxt, Inc., a biotech company, engages in the development and commercialization of technologies that focus on improving the health through monitoring and modulating the immune systems. The... more
NASDAQ 04/24/2025 4:00PM Eastern Quotes delayed